Clinical Trial Update: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial is evaluating pembrolizumab with or without Intismeran Autogene (V940) in participants with non-small cell lung cancer and is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Intismeran Autogene (V940)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: RECRUITING